2-(4-nitrobenzyl)propane-1,3-diol | 73344-98-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(4-nitrobenzyl)propane-1,3-diol
• 英文别名: 2-[(4-nitrophenyl)methyl]propane-1,3-diol
• CAS: 73344-98-6
• 化学式: C₁₀H₁₃NO₄
• 分子量: 211.218
• InChiKey: CCYJTBGSFAPPEK-UHFFFAOYSA-N

物化性质

• 沸点：
  418.2±30.0 °C(Predicted)
• 密度：
  1.299±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  86.3
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(4-nitrobenzyl)propane-1,3-diol 在 palladium on activated charcoal sodium azide 、 氢气 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 120.0 ℃ 、413.69 kPa 条件下， 反应 21.25h， 生成 2-(4'-aminobenzyl)propane-1,3-diamine
  参考文献：
  名称：

  DNA-directed alkylating agents. 2. Synthesis and biological activity of platinum complexes linked to 9-anilinoacridine

  摘要：

  Two different classes of cis-diaminedichloroplatinum(II) complexes linked to the DNA-intercalating chromophore 9-anilinoacridine have been synthesized and evaluated as DNA-targeted antitumor agents. Two different Pt chelating ligands were investigated (based on 1,2-ethanediamine and 1,3-propanediamine), designed to deliver the Pt in an orientation likely to respectively enhance either intrastrand or interstrand cross-linking. Although both sets of ligands were somewhat unstable under neutral or basic conditions with respect to disproportionation, the corresponding Pt complexes, once prepared, appeared to be quite stable. All the Pt complexes were monitored for purity by TLC, HPLC, and FAB mass spectra, and the mode of Pt coordination was established by 195Pt NMR spectroscopy. The complexes appeared to cause simultaneous platination and intercalative unwinding of plasmid DNA. In vitro studies were carried out with both wild-type and cisplatin-resistant P388 cell lines. Whereas cisplatin itself and the ethylenediamine and 1,3-propanediamine complexes used as standards were about 10-fold less active against the resistant line, the ethylenediamine-linked Pt complexes showed no differential toxicity between the two lines and the propanediamine-linked complexes showed significant differentials (up to 8-fold) in favor of the cisplatin-resistant line. However, these were no greater than those shown by the unplatinated ligands themselves. The majority of the acridine complexes were inactive in vivo against the wild-type P388 leukemia. They were very insoluble, and although a suitable formulation was found, this may have been a factor. It is also possible that these compounds bind in such a way as to direct the Pt away from the major groove.

  DOI：

  10.1021/jm00173a015
• 作为产物：
  描述：

  对硝基苄基丙二酸二甲酯 在 二异丁基氢化铝 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 2.5h， 以69%的产率得到2-(4-nitrobenzyl)propane-1,3-diol
  参考文献：
  名称：

  227 227络合的有效螯合剂

  摘要：

  我们提出了一种高效的or螯合剂的合成与表征，该che螯合剂是由八齿羟基吡啶酮类化合物衍生而来的。螯合剂在存在Th-227时（环境温度20分钟）以极快的形成速率形成极其稳定的络合物。另外，提供了小鼠生物分布数据，其表明螯合剂的快速肝胆排泄途径，其与低骨吸收一起支持了复合物在体内的稳定性。通过诸如抗体之类的生物分子中赖氨酸残基的α-氨基可以容易地活化该羧酸基团以进行缀合。这种螯合剂是目前在肿瘤学领域正在开发的新型靶向Thor缀合物（TTC）的重要组成部分。

  DOI：

  10.1016/j.bmcl.2016.07.034

文献信息

• [EN] RADIO-PHARMACEUTICAL COMPLEXES<br/>[FR] COMPLEXES RADIOPHARMACEUTIQUES
  申请人：BAYER PHARMA AG

  公开号：WO2017162555A1

  公开（公告）日：2017-09-28

  The invention provides a method for the formation of a tissue-targeting thorium complex, said method comprising; a) forming an octadentate chelator comprising four hydroxypyridinone (HOPO) moieties, substituted in the N-position with a methyl group, and a coupling moiety terminating in a carboxylic acid group; b) coupling said octadentate chelator to at least one tissue-targeting moiety targeting HER2; and c) contacting said tissue-targeting chelator with an aqueous solution comprising an ion of at least one alpha-emitting thorium isotope. A method of treatment of a neoplastic or hyperplastic disease comprising admistration of such a tissue-targeting thorium complex, as well as the complex and corresponding pharmaceutical formulations are also provided

  该发明提供了一种形成组织靶向钍配合物的方法，所述方法包括：a)形成一个含有四个羟基吡啶酮（HOPO）基团的八齿螯合剂，N-位置上取代有一个甲基基团，并且末端具有一个羧基的偶联基团；b)将所述八齿螯合剂偶联到至少一个靶向HER2的组织靶向基团上；c)将所述组织靶向螯合剂与含有至少一个α放射性钍同位素离子的水溶液接触。还提供了一种治疗肿瘤性或增生性疾病的方法，包括给予这种组织靶向钍配合物的治疗，同时还提供了该配合物及相应的制药配方。
• [EN] RADIO-PHARMACEUTICAL COMPLEXES<br/>[FR] COMPLEXES RADIO-PHARMACEUTIQUES
  申请人：BAYER AS

  公开号：WO2016096843A1

  公开（公告）日：2016-06-23

  The invention provides a method for the formation of a tissue-targeting thorium complex, said method comprising; a) forming an octadentate chelator comprising four hydroxypyridinone (HOPO) moieties, substituted in the N-position with a C l-C 3alkyl group, and a coupling moiety terminating in a carboxylic acid group; b) coupling said octadentate chelator to at least one tissue-targeting peptide or protein comprising at least one amine moiety by means of at least one amide-coupling reagent whereby to generate a tissue-targeting chelator; and c) contacting said tissue-targeting chelator with an aqueous solution comprising an ion of at least one alpha-emitting thorium isotope. A method of treatment of a neoplastic or hyperplastic disease comprising administration of such a tissue-targeting thorium complex, as well as the complex and corresponding pharmaceutical formulations are also provided.

  本发明提供了一种形成针对组织的目标性钍配合物的方法，所述方法包括：a）形成一种八齿配体，该配体包括四个被C1-C3烷基取代的N位的羟基吡啶酮（HOPO）基团，以及一个以羧酸基团终止的偶联部分；b）通过至少一种酰胺偶联试剂将所述八齿配体与至少一种包含至少一个胺基团的组织靶向肽或蛋白偶联，从而生成一种组织靶向配体；c）将所述组织靶向配体与包含至少一种α发射钍同位素离子的水溶液接触。本发明还提供了一种治疗肿瘤或增生性疾病的方法，包括施用这样的组织靶向钍配合物，以及相应的配合物和药物制剂。
• ALPHA-EMITTING COMPLEXES
  申请人：Ramdahl Thomas

  公开号：US20130183235A1

  公开（公告）日：2013-07-18

  The present invention provides a tissue-targeting complex comprising a tissue targeting moiety, an octadentate hydroxypyridinone-containing ligand and the ion of an alpha-emitting thorium radionuclide. The invention additionally provides therapeutic methods employing such complexes, methods of their production and use, and kits and pharmaceutical compositions comprising such complexes.

  本发明提供了一种组织靶向复合物，包括一个组织靶向基团、一个含有八齿羟基吡啶酮的配体和一个α放射性钍放射性核素的离子。此外，本发明还提供了使用这种复合物的治疗方法、其生产和使用方法，以及包含这种复合物的试剂盒和药物组合物。
• Alpha-emitting complexes
  申请人：Ramdahl Thomas

  公开号：US09724436B2

  公开（公告）日：2017-08-08

  The present invention provides a tissue-targeting complex comprising a tissue targeting moiety, an octadentate hydroxypyridinone-containing ligand and the ion of an alpha-emitting thorium radionuclide. The invention additionally provides therapeutic methods employing such complexes, methods of their production and use, and kits and pharmaceutical compositions comprising such complexes.

  本发明提供了一种组织靶向复合物，包括组织靶向基团、含有八齿羟基吡啶酮配体以及α放射性钍放射性核素离子。该发明还提供了利用这种复合物的治疗方法、其生产和使用方法，以及包含这种复合物的试剂盒和药物组合物。
• NOVEL TETRAAZA MACROCYCLIC COMPOUND, PREPARATION METHOD THEREOF AND USE THEREOF
  申请人：Yoo Jeong Soo

  公开号：US20120219495A1

  公开（公告）日：2012-08-30

  Provided are a cross-bridged tetraaza macrocyclic compound of a novel structure that can be used, for example, as a contrast agent for diagnostic imaging or a radiopharmaceutical and a method for preparing the same. The disclosed tetraaza macrocyclic compound is able to form a stable metal complex at a lower temperature and allows easy conjugation with a bioactive substance or a chemically active substance, when compared to the existing cross-bridged tetraaza macrocyclic compounds.

  提供的是一种新结构的交桥四氮杂大环化合物，可用作诊断成像的造影剂或放射性药物，以及一种制备该化合物的方法。所披露的四氮杂大环化合物能够在较低温度下形成稳定的金属配合物，并且与生物活性物质或化学活性物质相比，易于共轭。